Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Luis Prats-Sanchez, Pol Camps-Renom, Philip S Nash, Duncan Wilson, Gareth Ambler, Jonathan G Best, Marina Guasch-Jiménez, Anna Ramos-Pachón, Alejandro Martinez-Domeño, Álvaro Lambea-Gil, Garbiñe Ezcurra Díaz, Daniel Guisado-Alonso, Houwei Du, Rustam Al-Shahi Salman, Hans Rolf Jäger, Gregory Y Lip, Hakan Ay, Simon Jung, Natan M Bornstein, Thomas Gattringer, Sebastian Eppinger, Dianne H van Dam-Nolen, Masatoshi Koga, Kazunori Toyoda, Felix Fluri, Thanh G Phan, Velandai K Srikanth, Ji Hoe Heo, Hee-Joon Bae, Peter J Kelly, Toshio Imaizumi, Julie Staals, Sebastian Köhler, Yusuke Yakushiji, Dilek Necioglu Orken, Eric E Smith, Joanna M Wardlaw, Francesca M Chappell, Stephen D Makin, Jean-Louis Mas, David Calvet, Régis Bordet, Christopher P Chen, Roland Veltkamp, Nagaendran Kandiah, Robert J Simister, Frank-Erik De Leeuw, Stefan T Engelter, Nils Peters, Yannie O Soo, Annaelle Zietz, Jeroen Hendrikse, Werner H Mess, David J Werring, Joan Marti-Fabregas
BACKGROUND AND OBJECTIVES: The association between statin use and the risk of intracranial hemorrhage (ICrH) following ischemic stroke (IS) or transient ischemic attack (TIA) in patients with cerebral microbleeds (CMBs) remains uncertain. This study investigated the risk of recurrent IS and ICrH in patients receiving statins based on the presence of CMBs. METHODS: We conducted a pooled analysis of individual patient data from the Microbleeds International Collaborative Network, comprising 32 hospital-based prospective studies fulfilling the following criteria: adult patients with IS or TIA, availability of appropriate baseline MRI for CMB quantification and distribution, registration of statin use after the index stroke, and collection of stroke event data during a follow-up period of ≥3 months...
April 9, 2024: Neurology
#2
REVIEW
Xin Ding, Xu He, Bulang Tang, Tian Lan
Traditional Chinese medicine (TCM) has been widely used for several centuries for metabolic diseases, including non-alcoholic fatty liver disease (NAFLD). At present, NAFLD has become the most prevalent form of chronic liver disease worldwide and can progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. However, there is still a lack of effective treatment strategies in Western medicine. The development of NAFLD is driven by multiple mechanisms, including genetic factors, insulin resistance, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, inflammation, gut microbiota dysbiosis, and adipose tissue dysfunction...
February 3, 2024: Chinese Medicine
#3
REVIEW
Zahra Eslami, Samaneh Sadat Aghili, Amir Ghaleh Ghafi
Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in the liver, often related to obesity and insulin resistance, which can lead to inflammation and scarring of the liver tissue. While efforts have been made to develop effective treatments for NAFLD, the need for pharmaceutical interventions remains unmet. Large clinical trials investigating the association between statin use and NAFLD are scarce, leading to contradictory results. Statins play a crucial role in cholesterol synthesis in the liver...
January 2024: Chonnam Medical Journal
#4
JOURNAL ARTICLE
Waseem Amjad, Zhenghui Jiang, Michelle Lai
BACKGROUND AND AIM: Statin use has shown a reduction in hepatic decompensation and portal hypertension. Its association with portal vein thrombosis (PVT) incidence is unknown. We aim to compare the incidence of PVT in patients with and without statin use. METHODS: We excluded patients with a history of hepatocellular cancer, liver transplants, Budd-Chiari syndrome, and intra-abdominal malignancies. Patients with cirrhosis were followed from their first hepatologist clinical encounter (January 1, 2016, to January 31, 2021) for 180 days to determine PVT incidence...
January 25, 2024: Journal of Gastroenterology and Hepatology
#5
REVIEW
Shima Dowla Anwar, Christy Foster, Ambika Ashraf
Dyslipidemia has been linked metabolic-associated fatty liver disease (MAFLD). Several genes and transcription factors involved in lipid metabolism can increase susceptibility to MAFLD. Multiple parallel 'hits' have been proposed for developing hepatic steatosis, NASH, and MAFLD, including insulin resistance and subsequent free fatty acid excess, de novo lipogenesis, and excessive hepatic triglyceride and cholesterol deposition in the liver. This lead to defective beta-oxidation in the mitochondria and VLDL export and increased inflammation...
September 2023: Endocrinology and Metabolism Clinics of North America
#6
JOURNAL ARTICLE
Win Min Han, Tanakorn Apornpong, Hay Mar Su Lwin, Siwat Thammapiwan, Jedsadakorn Boonrungsirisap, Sivaporn Gatechompol, Sasiwimol Ubolyam, Pisit Tangkijvanich, Stephen J Kerr, Anchalee Avihingsanon
BACKGROUND: We investigated the association between nonalcoholic fatty liver disease (NAFLD) plus or minus a concurrent diagnosis of nonalcoholic steatohepatitis (NASH) and incident diabetes mellitus (DM) and the risk factors associated with NAFLD or NASH development. METHODS: In this prospective study, we analyzed people with human immunodeficiency virus (HIV; PWH) aged ≥18 years without excessive alcohol consumption or hepatitis coinfections. NAFLD was defined as controlled attenuation parameter ≥248 dB/m, whereas NASH with significant disease activity and liver fibrosis was defined as a FibroScan-AST score ≥0...
December 15, 2023: Clinical Infectious Diseases
#7
REVIEW
Ilias D Vachliotis, Stergios A Polyzos
PURPOSE OF REVIEW: To summarize experimental and clinical evidence on the association between tumor necrosis factor-α (TNF-α) and nonalcoholic fatty liver disease (NAFLD) and discuss potential treatment considerations. RECENT FINDINGS: Experimental evidence suggests that TNF-α is a cytokine with a critical role in the pathogenesis of NAFLD. Although, the production of TNF-α may be an early event during the course of nonalcoholic fatty liver (NAFL), TNF-α may play a more substantial role in the pathogenesis of nonalcoholic steatohepatitis (NASH) and NAFLD-associated fibrosis...
July 5, 2023: Current Obesity Reports
#8
JOURNAL ARTICLE
Nuha A ElSayed, Grazia Aleppo, Vanita R Aroda, Raveendhara R Bannuru, Florence M Brown, Dennis Bruemmer, Billy S Collins, Kenneth Cusi, Marisa E Hilliard, Diana Isaacs, Eric L Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K Lyons, Mary Lou Perry, Priya Prahalad, Richard E Pratley, Jane Jeffrie Seley, Robert C Stanton, Robert A Gabbay
No abstract text is available yet for this article.
September 1, 2023: Diabetes Care
#9
JOURNAL ARTICLE
Karishma Shelley, Amy Articolo, Rakesh Luthra, Michael Charlton
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is the more severe, inflammatory type of nonalcoholic fatty liver disease (NAFLD). NASH, a leading indication for liver transplantation, is growing in prevalence. The extent of liver fibrosis, ranging from fibrosis stage (FS) of none (F0) to cirrhosis (F4), is a strong predictor of health outcomes. There is little information on patient demographics and clinical characteristics by fibrosis stage and NASH treatment outside of academic medical centers...
May 19, 2023: BMC Gastroenterology
#10
JOURNAL ARTICLE
José A Inia, Geurt Stokman, Elsbet J Pieterman, Martine C Morrison, Aswin L Menke, Lars Verschuren, Martien P M Caspers, Martin Giera, J Wouter Jukema, Anita M van den Hoek, Hans M G Princen
Patients with metabolic syndrome are often prescribed statins to prevent the development of cardiovascular disease. Conversely, data on their effects on non-alcoholic steatohepatitis (NASH) are lacking. We evaluated these effects by feeding APOE*3-Leiden mice a Western-type diet (WTD) with or without atorvastatin to induce NASH and hepatic fibrosis. Besides the well-known plasma cholesterol lowering (-30%) and anti-atherogenic effects (severe lesion size -48%), atorvastatin significantly reduced hepatic steatosis (-22%), the number of aggregated inflammatory cells in the liver (-80%) and hepatic fibrosis (-92%) compared to WTD-fed mice...
April 25, 2023: International Journal of Molecular Sciences
#11
JOURNAL ARTICLE
Weiwei Dai, Baohong Xu, Peng Li, Junhua Weng
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has become more common as a result of changes in dietary structure and lifestyle. It is now the most common chronic liver disease both in China and in the rest of the world (NAFLD is also of concern in European and American countries). STUDY QUESTION: NAFLD and nonalcoholic steatohepatitis (NASH) are different stages of fatty liver disease. There is currently a lack of consensus on the use of statin therapy. We conducted a meta-analysis to evaluate the efficacy of statins in the treatment of NAFLD and NASH...
January 2023: American Journal of Therapeutics
#12
JOURNAL ARTICLE
Ibrahim Ayada, Laurens A van Kleef, Huai Zhang, Kuan Liu, Pengfei Li, Yasir J Abozaid, Marla Lavrijsen, Harry L A Janssen, Luc J W van der Laan, Mohsen Ghanbari, Maikel P Peppelenbosch, Ming-Hua Zheng, Robert J de Knegt, Qiuwei Pan
BACKGROUND: Statin use could benefit patients with non-alcoholic fatty liver disease (NAFLD), but the evidence is segmented and inconclusive. This multidimensional study comprehensively investigated the potential benefits and mechanism-of-action of statins in NAFLD. METHODS: A cross-sectional investigation was performed within the Rotterdam Study (general population; n = 4.576) and the PERSONS cohort (biopsy-proven NAFLD patients; n = 569). Exclusion criteria were secondary causes for steatosis and insufficient data on alcohol, dyslipidemia or statin use...
December 8, 2022: EBioMedicine
#13
JOURNAL ARTICLE
Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, Christophe Bureau, Eric Lawitz, Manal Abdelmalek, Naim Alkhouri, Sven Francque, Hugo Girma, Raphaël Darteil, Harold Couchoux, Myles Wolf, Arun Sanyal, Jacky Vonderscher, Pietro Scalfaro
BACKGROUND & AIMS: The LIVIFY trial investigated the safety, tolerability, and efficacy of vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist in patients with suspected fibrotic non-alcoholic steatohepatitis (NASH). METHODS: This double-blind phase IIa study was conducted in two parts. Patients were randomised (1:1:1:1) to receive placebo, vonafexor 100 mg twice daily (VONA-100BID), vonafexor 200 mg once daily (VONA-200QD), or 400 mg vonafexor QD (VONA-400QD) in Part A (safety run-in, pharmacokinetics/pharmacodynamics) or placebo, vonafexor 100 mg QD (VONA-100QD), or VONA-200QD (1:1:1) in Part B...
November 9, 2022: Journal of Hepatology
#14
JOURNAL ARTICLE
R Brett McQueen, Seth J Baum, Michael J Louie, William J Sasiela, Aikaterini Bilitou, Hemal Shah, Beth Nash, Kristin K Gillard, Kausik K Ray
BACKGROUND: Patients with atherosclerotic cardiovascular disease who require additional low-density lipoprotein cholesterol (LDL-C) lowering despite maximally tolerated statins have a significant unmet medical need and are at increased risk of future cardiovascular events and a reduced quality of life. OBJECTIVE: We aimed to estimate the percentage of cardiovascular events avoided following treatment with a fixed-dose combination of bempedoic acid plus ezetimibe (BA+EZE FDC) versus ezetimibe (EZE) in patients with atherosclerotic cardiovascular disease receiving maximally tolerated statins across a range of baseline LDL-C levels...
October 31, 2022: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
#15
JOURNAL ARTICLE
Amita Singh, Arielle P Davis, Breana Taylor, Steven Peters, David Tirschwell, W T Longstreth, Mahmud Mossa-Basha, Michael Nash, Sandeep P Khot
OBJECTIVES: Based on a 16-year case series, we sought lessons about diagnosis and treatment of cerebral fat embolism syndrome. MATERIALS AND METHODS: Using discharge codes at a Level 1 Trauma Center, we performed a retrospective chart review of clinical characteristics, diagnostic studies, treatments, and outcome in cerebral fat embolism syndrome. RESULTS: Thirty-nine (40%) of 97 patients with fat embolism syndrome were diagnosed with cerebral fat embolism syndrome, with 29 (74%) presenting with coma...
December 2022: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
#16
JOURNAL ARTICLE
Cheng Han Ng, Margaret Lp Teng, Nicholas Ws Chew, Kai En Chan, Jie Ning Yong, Jingxuan Quek, Darren Jun Hao Tan, Wen Hui Lim, Gabriel Sheng Jie Lee, Jessica Wong, Apichat Kaewdech, Daniel Q Huang, Jiongwei Wang, Mark Y Chan, Mazen Noureddin, Mohammad Shadab Siddiqui, Arun Sanyal, Mark Muthiah
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. NAFLD is associated with dyslipidemia, and cardiovascular mortality remains the leading cause of death. While statins are the first line therapy in hyperlipidemia, their utilization has been suboptimal. Hence, we examined the use of statins in NAFLD and mortality. RESEARCH DESIGN AND METHODS: Analysis was performed with National Health and Nutritional Examination Survey (NHANES) data from 1999 to 2018...
August 27, 2022: Expert Review of Gastroenterology & Hepatology
#17
REVIEW
Gashaw Hassen, Abhishek Singh, Gizeshwork Belete, Nidhi Jain, Ivonne De la Hoz, Genesis P Camacho-Leon, Nitsuh K Dargie, Keila G Carrera, Tadesse Alemu, Sharan Jhaveri, Nebiyou Solomon
Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extra-hepatic complications/comorbidities. It is an independent risk factor for cardiovascular disease (CVD), increasing susceptibility to hypertension, atherosclerosis, arrhythmia, myocardial dysfunction, cardiac valve deformation, and venous thrombosis through putative mechanisms including systemic inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and altered lipid metabolism...
May 2022: Curēus
#18
JOURNAL ARTICLE
Xing-Zi Li, Shi-You Jiang, Guo-Qiang Li, Qian-Ru Jiang, Jue-Wan Li, Chen-Chen Li, Yu-Qin Han, Bao-Liang Song, Xin-Ran Ma, Wei Qi, Wen-Wei Qiu
HMG-CoA reductase (HMGCR) is the rate-limiting enzyme in cholesterol de novo biosynthesis and its degradation may bring therapeutic benefits for the treatment of cardiovascular disease (CVD) and nonalcoholic steatohepatitis (NASH). Before, we disclosed compound HMG499 as a potent HMGCR degrader, which could be a promising agent for treating CVD, however its side-effect of promoting cholesterol accumulation in cells should be eliminated before progression. Herein, a series of novel heterocyclic ring-fused analogs of HMG499 were synthesized and investigated for their activities of stimulating HMGCR degradation using a HMGCR (TM1-8)-GFP reporting system...
April 2, 2022: European Journal of Medicinal Chemistry
#19
REVIEW
Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
Atherogenic dyslipidemia is characterized by increased triglyceride-rich lipoproteins and low high-density lipoprotein cholesterol concentrations. It is highly prevalent in non-alcoholic fatty liver disease (NAFLD) and contributes to the increased cardiovascular risk associated with this condition. Alongside insulin resistance it plays an important pathogenetic role in NAFLD/non-alcoholic steatohepatitis (NASH) development and progression. It has been shown that cholesterol-lowering reduces cardiovascular risk more in NAFLD vs non-NAFLD high-risk individuals...
January 27, 2022: World Journal of Hepatology
#20
JOURNAL ARTICLE
Atsushi Kimura, Kenya Kamimura, Marina Ohkoshi-Yamada, Yoko Shinagawa-Kobayashi, Ryo Goto, Takashi Owaki, Chiyumi Oda, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai
OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is a disease entity with an increasing incidence, with involvement of several metabolic pathways. Various organs, including the liver, kidneys, and the vasculature, are damaged in NASH, indicating the urgent need to develop a standard therapy. Therefore, this study was conducted to investigate the effects of drugs targeting various metabolic pathways and their combinations on a high-fat diet (HFD)-induced NASH medaka model. METHODS: To investigate the effects of drugs on vascular structures, the NASH animal model was developed using the fli::GFP transgenic medaka fed with HFD at 20 mg/fish daily...
March 12, 2022: Biochemical and Biophysical Research Communications
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
